MedTrace Logo

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

NCT05131763 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2021-11-23

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.

Conditions

Interventions

BIOLOGICAL

NKG2D-based CAR T-cells

Autologous genetically modified anti-NKG2DLs CAR transduced T cells

Sponsors & Collaborators

  • KAEDI

    collaborator OTHER

  • Fudan University

    lead OTHER

Principal Investigators

  • kuaile zhao, doctor · Fudan University

  • Changchun Cai, doctor · Xunyang Changchun Shihua Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-12-01
Completion
2023-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05131763 on ClinicalTrials.gov